Characteristics of patients with and without CEBPA mutations
| Patient characteristics for analyzed patients, CCG-2941, CCG-2961, and COG-AAML03P1 . | CEBPA mutation, n = 38 . | No CEBPA mutation, n = 809 . | P . |
|---|---|---|---|
| Sex, no. (%) | |||
| Male | 19 (50) | 429 (53) | .715 |
| Female | 19 (50) | 380 (47) | |
| Median age, y (range) | 13.5 (0.5-17.9) | 10.0 (0.01-21.6) | .004 |
| 0-2 y, no. (%) | 4 (11) | 193 (24) | .075 |
| 3-10 y, no. (%) | 7 (18) | 251 (31) | .099 |
| 11-21 y, no. (%) | 27 (71) | 365 (45) | .002 |
| Median WBC, ×109/L (range) | 22.9 (3.5- 283.6) | 21.9 (0.3-3260) | .354 |
| Median BM blasts, % (range) | 66.5 (21-94) | 70 (0-100) | .242 |
| Median platelets, ×109/L (range) | 29 (5-450) | 49 (2-460) | .002 |
| Median hemoglobin, g/L (range) | 95 (46-259) | 82 (4-307) | .004 |
| CNS disease, no. (%) | 2 (5) | 46 (6) | .912 |
| FLT3/ITD+, no. (%) | 2 (6) | 95 (12) | .300 |
| WT1 mutation, no. (%) | 3 (9) | 62 (8) | .743 |
| NPM1 mutation, no. (%) | 1 (3) | 56 (8) | .502 |
| Response to induction, no. (%) | |||
| CR | 32 (84) | 629 (80) | .518 |
| Not in CR | 6 (16) | 158 (20) | |
| Not evaluable | 0 | 22 | |
| Treatment outcome, % ± 2SE | |||
| 5-year OS | 83 ± 13 | 51 ± 5 | .023 |
| 5-year EFS | 70 ± 16 | 38 ± 4 | .015 |
| 5-year DFS | 74 ± 17 | 47 ± 5 | .065 |
| 5-year RR | 13 ± 14 | 44 ± 5 | .007 |
| Patient characteristics for analyzed patients, CCG-2941, CCG-2961, and COG-AAML03P1 . | CEBPA mutation, n = 38 . | No CEBPA mutation, n = 809 . | P . |
|---|---|---|---|
| Sex, no. (%) | |||
| Male | 19 (50) | 429 (53) | .715 |
| Female | 19 (50) | 380 (47) | |
| Median age, y (range) | 13.5 (0.5-17.9) | 10.0 (0.01-21.6) | .004 |
| 0-2 y, no. (%) | 4 (11) | 193 (24) | .075 |
| 3-10 y, no. (%) | 7 (18) | 251 (31) | .099 |
| 11-21 y, no. (%) | 27 (71) | 365 (45) | .002 |
| Median WBC, ×109/L (range) | 22.9 (3.5- 283.6) | 21.9 (0.3-3260) | .354 |
| Median BM blasts, % (range) | 66.5 (21-94) | 70 (0-100) | .242 |
| Median platelets, ×109/L (range) | 29 (5-450) | 49 (2-460) | .002 |
| Median hemoglobin, g/L (range) | 95 (46-259) | 82 (4-307) | .004 |
| CNS disease, no. (%) | 2 (5) | 46 (6) | .912 |
| FLT3/ITD+, no. (%) | 2 (6) | 95 (12) | .300 |
| WT1 mutation, no. (%) | 3 (9) | 62 (8) | .743 |
| NPM1 mutation, no. (%) | 1 (3) | 56 (8) | .502 |
| Response to induction, no. (%) | |||
| CR | 32 (84) | 629 (80) | .518 |
| Not in CR | 6 (16) | 158 (20) | |
| Not evaluable | 0 | 22 | |
| Treatment outcome, % ± 2SE | |||
| 5-year OS | 83 ± 13 | 51 ± 5 | .023 |
| 5-year EFS | 70 ± 16 | 38 ± 4 | .015 |
| 5-year DFS | 74 ± 17 | 47 ± 5 | .065 |
| 5-year RR | 13 ± 14 | 44 ± 5 | .007 |